Reducing suicide risk in schizophrenia: Focus on the role of clozapine

H. Y. Meltzer*, R. Anand, L. Alphs

*Corresponding author for this work

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The risk of suicide is a major factor in the morbidity and mortality of schizophrenia, accounting for approximately 10% of deaths in patients with this condition. Indicated risk factors include male gender, social isolation, depression, feelings of hopelessness, a history of suicide attempts, deteriorating health and, uniquely to patients with schizophrenia, young age in men and chronic schizophrenia with numerous exacerbations. There is significant evidence suggesting that clozapine, the gold standard treatment for patients with treatment-resistant schizophrenia, reduces the suicide rate. Although the reasons for this are unknown, beneficial effects of clozapine that are thought to contribute to the reduced suicide rate include improved symptom control, reduced extrapyramidal symptoms, direct antidepressant action, improved cognitive function, and improved compliance. These improve self-perceived quality of life and hence lead to greater desire, and capacity, to survive. Reduced suicide attempts and completed suicide may also reflect the effect of weekly contact with mental health providers to obtain blood for white blood cell monitoring or cohort effects (i.e. time-dependent decrease in suicide attempt rates). Data from a number of studies which have investigated the impact of clozapine on suicide rates in patients with schizophrenia demonstrate that the drug reduces the risk of suicide attempts by approximately 75 to 80%. It had a comparable effect in reducing the completed suicide rate in an epidemiological survey of all US patients in the Clozaril® National Registry. A large scale prospective, randomised study comparing clozapine and olanzapine in patients with a recent history of suicidality is in process. The International Suicide Prevention Trial (InterSePT) will compare the effectiveness of clozapine (300 to 900 mg/day) with olanzapine (10 to 20 mg/day) in reducing suicide and suicide-related events in patients with schizophrenia and schizoaffective disorder. An overview of the study methodology is provided in this review.

Original languageEnglish (US)
Pages (from-to)355-365
Number of pages11
JournalCNS Drugs
Volume14
Issue number5
DOIs
StatePublished - Jan 1 2000

Fingerprint

Clozapine
Suicide
Schizophrenia
olanzapine
Cohort Effect
Social Isolation
Psychotic Disorders
Cognition
Antidepressive Agents
Compliance
Registries
Mental Health
Emotions
Leukocytes

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Meltzer, H. Y. ; Anand, R. ; Alphs, L. / Reducing suicide risk in schizophrenia : Focus on the role of clozapine. In: CNS Drugs. 2000 ; Vol. 14, No. 5. pp. 355-365.
@article{0c74dd40b4e84f4494a97c7d996271ae,
title = "Reducing suicide risk in schizophrenia: Focus on the role of clozapine",
abstract = "The risk of suicide is a major factor in the morbidity and mortality of schizophrenia, accounting for approximately 10{\%} of deaths in patients with this condition. Indicated risk factors include male gender, social isolation, depression, feelings of hopelessness, a history of suicide attempts, deteriorating health and, uniquely to patients with schizophrenia, young age in men and chronic schizophrenia with numerous exacerbations. There is significant evidence suggesting that clozapine, the gold standard treatment for patients with treatment-resistant schizophrenia, reduces the suicide rate. Although the reasons for this are unknown, beneficial effects of clozapine that are thought to contribute to the reduced suicide rate include improved symptom control, reduced extrapyramidal symptoms, direct antidepressant action, improved cognitive function, and improved compliance. These improve self-perceived quality of life and hence lead to greater desire, and capacity, to survive. Reduced suicide attempts and completed suicide may also reflect the effect of weekly contact with mental health providers to obtain blood for white blood cell monitoring or cohort effects (i.e. time-dependent decrease in suicide attempt rates). Data from a number of studies which have investigated the impact of clozapine on suicide rates in patients with schizophrenia demonstrate that the drug reduces the risk of suicide attempts by approximately 75 to 80{\%}. It had a comparable effect in reducing the completed suicide rate in an epidemiological survey of all US patients in the Clozaril{\circledR} National Registry. A large scale prospective, randomised study comparing clozapine and olanzapine in patients with a recent history of suicidality is in process. The International Suicide Prevention Trial (InterSePT) will compare the effectiveness of clozapine (300 to 900 mg/day) with olanzapine (10 to 20 mg/day) in reducing suicide and suicide-related events in patients with schizophrenia and schizoaffective disorder. An overview of the study methodology is provided in this review.",
author = "Meltzer, {H. Y.} and R. Anand and L. Alphs",
year = "2000",
month = "1",
day = "1",
doi = "10.2165/00023210-200014050-00003",
language = "English (US)",
volume = "14",
pages = "355--365",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "5",

}

Reducing suicide risk in schizophrenia : Focus on the role of clozapine. / Meltzer, H. Y.; Anand, R.; Alphs, L.

In: CNS Drugs, Vol. 14, No. 5, 01.01.2000, p. 355-365.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Reducing suicide risk in schizophrenia

T2 - Focus on the role of clozapine

AU - Meltzer, H. Y.

AU - Anand, R.

AU - Alphs, L.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The risk of suicide is a major factor in the morbidity and mortality of schizophrenia, accounting for approximately 10% of deaths in patients with this condition. Indicated risk factors include male gender, social isolation, depression, feelings of hopelessness, a history of suicide attempts, deteriorating health and, uniquely to patients with schizophrenia, young age in men and chronic schizophrenia with numerous exacerbations. There is significant evidence suggesting that clozapine, the gold standard treatment for patients with treatment-resistant schizophrenia, reduces the suicide rate. Although the reasons for this are unknown, beneficial effects of clozapine that are thought to contribute to the reduced suicide rate include improved symptom control, reduced extrapyramidal symptoms, direct antidepressant action, improved cognitive function, and improved compliance. These improve self-perceived quality of life and hence lead to greater desire, and capacity, to survive. Reduced suicide attempts and completed suicide may also reflect the effect of weekly contact with mental health providers to obtain blood for white blood cell monitoring or cohort effects (i.e. time-dependent decrease in suicide attempt rates). Data from a number of studies which have investigated the impact of clozapine on suicide rates in patients with schizophrenia demonstrate that the drug reduces the risk of suicide attempts by approximately 75 to 80%. It had a comparable effect in reducing the completed suicide rate in an epidemiological survey of all US patients in the Clozaril® National Registry. A large scale prospective, randomised study comparing clozapine and olanzapine in patients with a recent history of suicidality is in process. The International Suicide Prevention Trial (InterSePT) will compare the effectiveness of clozapine (300 to 900 mg/day) with olanzapine (10 to 20 mg/day) in reducing suicide and suicide-related events in patients with schizophrenia and schizoaffective disorder. An overview of the study methodology is provided in this review.

AB - The risk of suicide is a major factor in the morbidity and mortality of schizophrenia, accounting for approximately 10% of deaths in patients with this condition. Indicated risk factors include male gender, social isolation, depression, feelings of hopelessness, a history of suicide attempts, deteriorating health and, uniquely to patients with schizophrenia, young age in men and chronic schizophrenia with numerous exacerbations. There is significant evidence suggesting that clozapine, the gold standard treatment for patients with treatment-resistant schizophrenia, reduces the suicide rate. Although the reasons for this are unknown, beneficial effects of clozapine that are thought to contribute to the reduced suicide rate include improved symptom control, reduced extrapyramidal symptoms, direct antidepressant action, improved cognitive function, and improved compliance. These improve self-perceived quality of life and hence lead to greater desire, and capacity, to survive. Reduced suicide attempts and completed suicide may also reflect the effect of weekly contact with mental health providers to obtain blood for white blood cell monitoring or cohort effects (i.e. time-dependent decrease in suicide attempt rates). Data from a number of studies which have investigated the impact of clozapine on suicide rates in patients with schizophrenia demonstrate that the drug reduces the risk of suicide attempts by approximately 75 to 80%. It had a comparable effect in reducing the completed suicide rate in an epidemiological survey of all US patients in the Clozaril® National Registry. A large scale prospective, randomised study comparing clozapine and olanzapine in patients with a recent history of suicidality is in process. The International Suicide Prevention Trial (InterSePT) will compare the effectiveness of clozapine (300 to 900 mg/day) with olanzapine (10 to 20 mg/day) in reducing suicide and suicide-related events in patients with schizophrenia and schizoaffective disorder. An overview of the study methodology is provided in this review.

UR - http://www.scopus.com/inward/record.url?scp=0033710960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033710960&partnerID=8YFLogxK

U2 - 10.2165/00023210-200014050-00003

DO - 10.2165/00023210-200014050-00003

M3 - Review article

AN - SCOPUS:0033710960

VL - 14

SP - 355

EP - 365

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 5

ER -